Coeptis Therapeutics Inc. (OTCPK:COEP) agreed to acquire TLR5 Immunity Receptor Agnonist Platform from Statera Biopharma, Inc. (NasdaqCM:STAB) for $6 million on April 6, 2022. The consummation of the transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a financing contingency.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.29 USD | -1.23% |
|
-10.66% | -63.01% |
06-17 | Ladenburg Downgrades Coeptis Therapeutics to Neutral From Buy | MT |
06-14 | Coeptis Therapeutics Holdings, Inc. announced that it has received $4.3 million in funding | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
0.29 USD | -1.23% | -10.66% | 10.76M | ||
0.0006 USD | 0.00% | 0.00% | 43.55K | ||
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-63.01% | 10.76M | |
+54.61% | 811B | |
+43.50% | 640B | |
-6.33% | 353B | |
+20.62% | 333B | |
+10.44% | 302B | |
+17.60% | 246B | |
+2.54% | 225B | |
+12.65% | 218B | |
+8.61% | 168B |
- Stock Market
- Equities
- COEP Stock
- News Coeptis Therapeutics Holdings, Inc.
- Coeptis Therapeutics Inc. agreed to acquire TLR5 Immunity Receptor Agnonist Platform from Statera Biopharma, Inc. for $6 million.